Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.

Literature DB >> 22801969

Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.

Lillian Sung, Richard Aplenc, Todd A Alonzo, Robert B Gerbing, Alan S Gamis.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22801969 PMCID： PMC3487455 DOI： 10.3324/haematol.2012.065490

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

5 in total

1. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

Authors: U Creutzig; M Zimmermann; J Ritter; D Reinhardt; J Hermann; G Henze; H Jürgens; H Kabisch; A Reiter; H Riehm; H Gadner; G Schellong
Journal: Leukemia Date: 2005-12 Impact factor: 11.528

2. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis
Journal: Cancer Date: 2011-07-15 Impact factor: 6.860

3. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Authors: M J Greenwood; M D Seftel; C Richardson; D Barbaric; M J Barnett; H Bruyere; D L Forrest; D E Horsman; C Smith; K Song; H J Sutherland; C L Toze; T J Nevill; S H Nantel; D E Hogge
Journal: Leuk Lymphoma Date: 2006-07

4. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

Authors: Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal: Pediatrics Date: 2002-01 Impact factor: 7.124

5. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

Authors: J P Dutcher; C A Schiffer; P H Wiernik
Journal: J Clin Oncol Date: 1987-09 Impact factor: 44.544

5 in total

8 in total

1. The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia.

Authors: Rosa Nguyen; Sima Jeha; Yinmei Zhou; Xueyuan Cao; Cheng Cheng; Deepa Bhojwani; Patrick Campbell; Scott C Howard; Jeffrey Rubnitz; Raul C Ribeiro; John T Sandlund; Tanja Gruber; Hiroto Inaba; Ching-Hon Pui; Monika L Metzger
Journal: Pediatr Blood Cancer Date: 2016-05-17 Impact factor: 3.167

2. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.

Authors: Jason E Farrar; Heather L Schuback; Rhonda E Ries; Daniel Wai; Oliver A Hampton; Lisa R Trevino; Todd A Alonzo; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro Hermida; Donna M Muzny; Ninad Dewal; Navin Rustagi; Lora R Lewis; Alan S Gamis; David A Wheeler; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal: Cancer Res Date: 2016-03-03 Impact factor: 12.701

3. Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.

Authors: Lane H Miller; Frank Keller; Ann Mertens; Mitchel Klein; Kristen Allen; Sharon Castellino; William G Woods
Journal: Pediatr Blood Cancer Date: 2019-09-10 Impact factor: 3.167

Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.

1. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

2. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

3. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

4. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

5. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

1. The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia.

2. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.

3. Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.

4. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.

Review 5. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

6. Comments on chronic subdural hematoma in a child with acute myeloid leukemia after leukocytosis.

7. Sepsis-induced Hyperleukocytosis in a Preterm.

8. Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia.